Shots:
- Health Canada has granted NOC to Biocon‘s Bosaya (60mg/mL, SC, PFS) & Vevzuo (70mg/mL, SC, single-dose vial), biosimilar versions of Amgen’s Prolia & Xgeva (denosumab)
- Approval was based on extensive data, incl. analytical, nonclinical, & clinical data, showing that both biosimilars matched the reference product in quality, safety & efficacy
- Bosaya & Vevzuo are anti-RANKL monoclonal antibodies that will be available in 60mg/mL PFS & 70mg/mL single-dose vial presentation, respectively, for subcutaneous use
Ref: Businesswire | Image: Biocon | Press Release
Related News: Biocon Launches Bosaya and Aukelso (Biosimilar, Prolia & Xgeva) in the US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
